Twitter Explainer: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaBrendan Reardon·FollowPublished invanallenlab·1 min read·Apr 4, 2018--ShareFigure 2a: Mutations in the discovery cohort. Patients are ordered by response category, with tumor mutation burden in decreasing order within each response category. Shown are the genes that were recurrently mutated at a significant frequency, as assessed by MutSig2CV analysis (table S1E). CNA = copy number alteration.